Shiseido to Acquire Dr. Dennis Gross Skincare
Shiseido Company, Limited (The Prime Market of the Tokyo Stock Exchange: 4911) (“Shiseido”, “Company”) today announced that Shiseido Americas Corporation (“Shiseido Americas”), a subsidiary of Shiseido, has signed a definitive agreement to acquire DDG Skincare Holdings LLC, the owner of Dr. Dennis Gross Skincare brand which offers dermatologist-led, science-based prestige skincare that has revolutionized the beauty industry by bringing high-level products to consumers everywhere.
In support of Shiseido’s corporate mission, “BEAUTY INNOVATIONS FOR A BETTER WORLD”, the acquisition of Dr. Dennis Gross Skincare is a synergistic complement to the Company’s skin beauty strategic framework and global portfolio of prestige brands. With the addition of Dr. Dennis Gross Skincare, Shiseido seeks to accelerate and strengthen its core prestige skincare business which includes brands SHISEIDO and Clé de Peau Beauté.
Dr. Dennis Gross Skincare was launched in 2000 by former skin cancer researcher and practicing dermatologist, Dr. Dennis Gross, and his wife, Carrie Gross. Dr. Dennis Gross Skincare’s best-in-class products are distinctive and highly effective, leveraging active ingredients with proven skincare benefits. Dr. Dennis Gross Skincare values industry-changing innovation and has a philosophy that is rooted in research, dermatology, and technology.
As part of the Shiseido portfolio, Dr. Dennis Gross Skincare will leverage the Company’s vast global support network, commercial experience, and R&D expertise, enabling the brand to accelerate its ambitious growth plans. Shiseido’s proven expertise in skincare will facilitate Dr. Dennis Gross Skincare’s long-term growth trajectory. Additionally, this acquisition bolsters the Company’s geographic diversification and reinforces its investment in the Americas, with an aim to accelerate growth and increase profitability in the region.
Masahiko Uotani, Chairman and CEO of Shiseido, said, “This transaction is well-aligned with Shiseido’s 2030 goal of becoming a personal beauty wellness company that supports people in realizing unique beauty and wellness throughout their lives. Dr. Dennis Gross Skincare is the perfect complement to our global portfolio of prestige brands as their core values are aligned with ours in terms of their scientific and innovative approach to beauty and our people-first culture. We are thrilled to welcome the Dr. Dennis Gross Skincare team to the Shiseido family, and I am confident Dr. Dennis Gross Skincare will accelerate our growth in the Americas, a region that has experienced strong business performance, thanks to our portfolio of exceptional brands.”
Shiseido Americas President and CEO and Global M&A Leader for Shiseido, Ron Gee, added, “We have long-admired what Carrie Gross has built through innovation and disruption of the beauty industry as well as the unique way in which the brand delivers credible and effective products through research, accessibility and education. We are also excited to work with Dr. Dennis Gross, a practicing, world-renowned, board-certified dermatologist whose work has attracted a loyal and highly engaged consumer base. With our deep commitment to our teams and our consumers, I know Dr. Dennis Gross Skincare will thrive in the Shiseido portfolio.”
Dr. Gross, Co-Founder of Dr. Dennis Gross Skincare and Chief Science Officer and Carrie Gross, Co-Founder and Chief Executive Officer said, “We launched Dr. Dennis Gross Skincare in 2000 with the mission of making a difference in the lives of all people everywhere by helping them achieve healthier skin. We’ve built an incredible brand with a deep clinical foundation and loyal consumer base, and we are thrilled to have found a partner that shares our values. With its long and rich heritage blending beauty with science, Shiseido is the ideal home for Dr. Dennis Gross Skincare, and we look forward to partnering with the Shiseido team as we continue developing innovative products and skincare solutions that deliver visible results.”
The transaction was led by Shiseido Americas and the New York-based Shiseido Global M&A team, in close coordination with Shiseido Company, Limited, the Company’s headquarters. The transaction is subject to customary regulatory approvals and closing conditions and is expected to close in the first quarter of 2024. Terms of the transaction were not disclosed.
Jones Day served as Shiseido Americas’ legal counsel. Raymond James served as Dr. Dennis Gross Skincare’s exclusive financial advisor. Cowan, DeBaets, Abrahams & Sheppard LLP served as legal counsel to Dr. Dennis Gross Skincare, and Morrison Foerster served as legal counsel to certain of the shareholders.
About Shiseido Company, Limited
Shiseido was founded in 1872 as the first private Western-style pharmacy in Japan. The business gradually evolved into a cosmetics company, offering people the most advanced technology and the finest aesthetics available across the world. Now known globally as the premier cosmetics company with roots in Japan, the name Shiseido has come to represent the world’s highest standards of quality. Fiercely contemporary and innovative after over 150 years in business, Shiseido Group brands are now sold in over 120 countries and regions. With its new Medium-to-Long-Term Strategy “SHIFT 2025 and Beyond”, Shiseido aims to become a “PERSONAL BEAUTY WELLNESS COMPANY” by 2030, realizing its corporate mission, BEAUTY INNOVATIONS FOR A BETTER WORLD. For more information, please visit https://corp.shiseido.com/en/.
About Dr. Dennis Gross Skincare
Launched in New York City in 2000, Dr. Dennis Gross Skincare is a skincare brand founded by former skin cancer researcher and practicing dermatologist Dr. Dennis Gross along with his wife Carrie Gross. Together, they disrupted the beauty industry by asking people to peel daily with their now-iconic Alpha Beta® Daily Peels. With innovative, patented formulas incorporating simple, straightforward instructions, clients became instant believers. Today the Alpha Beta Peel is the #1 at-home peel in the US and a staple in the beauty cabinets of top celebrities, aestheticians, and makeup artists. Dr. Gross continues to bring innovations and expertise from the dermatology practice to retail consumers around the globe in the form of easy-to-use at home products designed to work together in customizable regimens to treat multiple concerns. For more information, visit the brand on Instagram, Facebook or at drdennisgross.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231222575305/en/
Contact information
For Shiseido Americas
Jadzia Zielinski Tirsch
Jonathan Leacock
jtirsch@sac.shiseido.com
jleacock@sac.shiseido.com
+1 212-805-2357
+1 212-805-1299
OR
FGS Global
Emily Claffey/Danya Al-Qattan/Bridget Nagle
Shiseido@fgsglobal.com
+1 212-687-8080
For Dr. Dennis Gross Skincare
Alyssa Keller D'Amico
Director of Content & Communications
alyssa.keller@dgskincare.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces European Commission Approval of Minjuvi ® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma17.12.2025 17:20:00 CET | Press Release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one line of systemic therapy. "The EC approval of Minjuvi addresses a critical need, bringing a new, first-of-its-kind, chemotherapy-free option to patients in Europe with relapsed or refractory FL,” said Bill Meury, President and Chief Executive Officer, Incyte. “Historically, FL patients have had limited treatment options in the second-line setting, and we are proud to drive this important advancement for the lymphoma community as we seek to deliver innovative medicines for patients with cancer.” The EC decision follows the positive opinion received from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in November 2025. This marks the second indication for Minjuvi, which was previo
Rigaku Launches ONYX 3200, a Metrology Instrument for Semiconductor Manufacturing17.12.2025 16:00:00 CET | Press Release
Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) announced the launch of the ONYX 3200, a new semiconductor metrology system to measure film thickness, composition and bump* structures for wafer-level processes. The system is engineered to help manufacturers stabilize quality and increase yield in the metal-wiring formation (back-end-of-line (BEOL)) and packaging processes of semiconductor chips. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216597402/en/ ONYX 3200 Due to accelerating demands for AI, high-performance computing, data centers, mobile devices, and other devices, chip wiring and interconnect structures have grown increasingly delicate and complex. As a result, the ability to accurately and non-destructively measure metal layers thinner than a human hair and bump
Taylor Wessing Diversifies Its International Strategy17.12.2025 15:05:00 CET | Press Release
International law firm Taylor Wessing is set to diversify its strategy within its international alliance, in order to push international growth and innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217415857/en/ Dr. Oliver Bertram, Global Co-Chair at Taylor Wessing The English part of the partnership is seeking a merger with US law firm Winston & Strawn and would – depending on a corresponding partner decision, which is still pending – leave the Taylor Wessing alliance at the end of April 2026. Both parties wish to continue their successful joint international client work unchanged. Therefore, collaboration between Taylor Wessing and future Anglo-American firm Winston Taylor will continue seamlessly based on a cooperation agreement, ensuring that clients will not experience any change in their collaboration with Taylor Wessing. With the firm’s new open strategy, Taylor Wessing equally meets the strategic requirem
ISACA to Lead Global Credentialing for CMMC Cybersecurity Framework as International Cyber Readiness Standards Rise17.12.2025 15:00:00 CET | Press Release
As cyber threats escalate and governments raise expectations around operational resilience, ISACA has been appointed to lead the global credentialing programme for the U.S. DoW’s Cybersecurity Maturity Model Certification (CMMC) program. The appointment positions ISACA – the international association for cybersecurity, audit and digital trust – as the exclusive CMMC Assessor and Instructor Certification Organization (CAICO), responsible for training, examining and certifying professionals, assessors, and instructors across the CMMC ecosystem. Originally developed by the U.S. DoW to protect sensitive unclassified information within its global supply chain, CMMC is increasingly relevant to European defence, aerospace, engineering and high-technology companies participating in transatlantic programmes. As the framework is phased into U.S. procurement from 2025 to 2028, many European organisations that handle Controlled Unclassified Information (CUI) or Federal Contract Information (FCI),
ASN Bank Signs a Contract With HCLTech to Accelerate Digital Transformation and Enhance Customer Experience17.12.2025 14:43:00 CET | Press Release
HCLTech, a leading global technology company, today announced that it has been selected as a strategic partner by ASN Bank (formerly de Volksbank), the fourth-largest retail bank in the Netherlands. As part of its new strategy ‘Simplify and Grow’, ASN Bank aims to modernise and standardise its IT architecture, which will involve consolidating IT services, simplifying the vendor landscape and building a future-ready organisation. Under the multi-year agreement, HCLTech will support ASN Bank’s enterprise applications, and streamline services through a distributed delivery model to enhance efficiency and customer experience. Michel Ruijterman, Chief Information Officer, ASN Bank: “By signing this agreement , HCLTech’s proven track record in delivering scalable, innovative solutions tailored to the financial services sector means we can now confidently press on with streamlining our business by reducing the number of existing products and aligning the underlying processes and systems under
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom